Mehrdad Bakhshayesh Karam1, Abtin Doroudinia2, Ali Safavi Nainee2, Fatemeh Kaghazchi2, Abbas Yousefi Koma2, Payam Mehrian2, Farahnaz Agha Hossein2. 1. Pediatric Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2. Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Abstract
INTRODUCTION: PET/CT scan has an emerging role in head and neck oncology with a few well-established indications, including: detection of unknown primary tumor site, tumor staging, radiotherapy planning, treatment response assessment and detection of recurrent disease. The purpose of this study is reporting PET/CT findings in head and neck cancer patients to emphasize its role in head and neck oncology. MATERIALS AND METHODS: In a retrospective study, we reviewed our PET/CT database and found 94 patients with primary head and neck cancer. This is a descriptive report of PET/CT scan findings in head and neck cancer patients referred to Masih Daneshvari hospital, Tehran, Iran between 2013 and 2016. RESULTS: The most common primary tumor sites were oral cavity (27%) and nasopharynx (22%). The most common indication for referral was tumor restaging (76%) including treatment response evaluation and differentiation between recurrence and post-treatment fibrosis. In 60% of patients with negative primary tumor site, PET/CT was able to detect evidence of regional or distant metastasis. PET/CT was able to localize the primary tumor site in 66% of patients with unknown primary tumor site. We also had 19 patients with primary head and neck cancer referred for initial staging, demonstrating evidence of metastasis in 66% of all cases. CONCLUSION: Most patients are referred for restaging and demonstrate evidence of regional or distant metastasis with significant value for further treatment planning. Providing insurance coverage and familiarizing referring physicians about correct indications of this relatively new diagnostic modality will be to the best interest of head and neck cancer patients in the long run.
INTRODUCTION: PET/CT scan has an emerging role in head and neck oncology with a few well-established indications, including: detection of unknown primary tumor site, tumor staging, radiotherapy planning, treatment response assessment and detection of recurrent disease. The purpose of this study is reporting PET/CT findings in head and neck cancerpatients to emphasize its role in head and neck oncology. MATERIALS AND METHODS: In a retrospective study, we reviewed our PET/CT database and found 94 patients with primary head and neck cancer. This is a descriptive report of PET/CT scan findings in head and neck cancerpatients referred to Masih Daneshvari hospital, Tehran, Iran between 2013 and 2016. RESULTS: The most common primary tumor sites were oral cavity (27%) and nasopharynx (22%). The most common indication for referral was tumor restaging (76%) including treatment response evaluation and differentiation between recurrence and post-treatment fibrosis. In 60% of patients with negative primary tumor site, PET/CT was able to detect evidence of regional or distant metastasis. PET/CT was able to localize the primary tumor site in 66% of patients with unknown primary tumor site. We also had 19 patients with primary head and neck cancer referred for initial staging, demonstrating evidence of metastasis in 66% of all cases. CONCLUSION: Most patients are referred for restaging and demonstrate evidence of regional or distant metastasis with significant value for further treatment planning. Providing insurance coverage and familiarizing referring physicians about correct indications of this relatively new diagnostic modality will be to the best interest of head and neck cancerpatients in the long run.
Authors: Simone Wegen; Lutz van Heek; Philipp Linde; Karina Claus; Dennis Akuamoa-Boateng; Christian Baues; Shachi Jenny Sharma; Klaus Schomäcker; Thomas Fischer; Katrin Sabine Roth; Jens Peter Klußmann; Simone Marnitz; Alexander Drzezga; Carsten Kobe Journal: Mol Imaging Biol Date: 2022-06-30 Impact factor: 3.488
Authors: Andreas Pabst; Daniel G E Thiem; Elisabeth Goetze; Alexander K Bartella; Michael T Neuhaus; Jürgen Hoffmann; Alexander-N Zeller Journal: Clin Oral Investig Date: 2021-03-29 Impact factor: 3.573